Belapectin (GR-MD-02)

About Galectin Therapeutics

Galectin Therapeutics' mission is to develop novel therapeutics for chronic liver disease and cancer by inhibiting the galectin-3 protein. Its primary achievement is advancing belapectin into a pivotal Phase 2b/3 trial (NAVIGATE) for MASH cirrhosis with portal hypertension, positioning it as a potential first-to-market therapy for this life-threatening condition. The company's strategy is to clinically validate its galectin-3 platform in high-need fibrotic and oncologic indications, creating significant value through targeted clinical development and potential strategic partnerships.

About Galectin Therapeutics

Galectin Therapeutics' mission is to develop novel therapeutics for chronic liver disease and cancer by inhibiting the galectin-3 protein. Its primary achievement is advancing belapectin into a pivotal Phase 2b/3 trial (NAVIGATE) for MASH cirrhosis with portal hypertension, positioning it as a potential first-to-market therapy for this life-threatening condition. The company's strategy is to clinically validate its galectin-3 platform in high-need fibrotic and oncologic indications, creating significant value through targeted clinical development and potential strategic partnerships.

Therapeutic Areas